RECORDATI ORD overview

Consolidated net revenue of € 1,743.1 million in the first nine months, +12.0% or +9.3% on a like-for-like basis (3) and at constant exchange rates (CER) EBITDA (1) of € 665.7 million, +11.8%, revenue margin of 38.2% Adjusted net income (2) of € 445.4 million, +9.5% Net income of € 338.4 million, +11.1% Free cash flow (4) at € 434.3 million, +€ 42.5 million vs prior year Net debt (5) at € 1,317.3 million, just below 1.6x EBITDA Financial targets for FY 2024 confirmed, excluding any...

Milan, 4 th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder. Enjaymo® (sutimlimab) is a humanized monoclonal antibody indicated for the treatment of hemolysis in adults with CAD. In 2022, it was granted approval by the U.S. Food and Drug Administration (FDA), the European...

Recordati Rare Diseases announce today publication of the long-term outcomes from the open-label extension period of the Phase III LINC 3 study of Isturisa® in The European Journal of Endocrinology . 1 These data support the long-term utility of Isturisa® in the maintenance treatment of patients with Cushing’s disease and reinforce Isturisa as an effective and well-tolerated oral therapy. Isturisa® is indicated in the EU for the treatment of adult patients with endogenous Cushing’s...

Recordati Rare Diseases announce today the publication of positive results from the Phase III LINC 4 study of Isturisa in The Journal of Clinical Endocrinology & Metabolism . 1 These data reinforce Isturisa as an effective and well-tolerated oral therapy for patients with Cushing’s disease. Isturisa is indicated in the EU for the treatment of adult patients with endogenous Cushing’s syndrome, 2 a rare and debilitating condition of hypercortisolism that is most commonly caused by a pituitary...

Recordati Rare Diseases announces that positive results from the Phase III LINC 4 study of Isturisa® were presented on March 22 at The Endocrine Society’s Annual Meeting. 1 Results from LINC 4, the first Phase III study in patients with Cushing’s disease to include an upfront, double-blind, randomised, placebo-controlled period, demonstrated that Isturisa® provided rapid and sustained normalisation of mean urinary free cortisol (mUFC) levels. 1 Normalising mUFC levels represents an...